Monte S Willis, Mauricio Rojas, Luge Li, Craig H Selzman, Ru-Hang Tang, William E Stansfield, Jessica E Rodriguez, David J Glass, Cam Patterson
Pathological cardiac hypertrophy, induced by various etiologies such as high blood pressure and aortic stenosis, develops in response to increased afterload and represents a common intermediary in the development of heart failure. Understandably then, the reversal of pathological cardiac hypertrophy is associated with a significant reduction in cardiovascular event risk and represents an important, yet underdeveloped, target of therapeutic research. Recently, we determined that muscle ring finger-1 (MuRF1), a muscle-specific protein, inhibits the development of experimentally induced pathological; cardiac hypertrophy...
April 2009: American Journal of Physiology. Heart and Circulatory Physiology